



IDKmonitor® ELISAs



Example of Drug Level ELISA



Example of Total Anti-Drug Antibody ELISA



Therapeutic Drug Monitoring

ELISAs

Cat. No.	Drug level ELISAs
K9655	IDKmonitor® Infliximab†
K9656	IDKmonitor® Golimumab
K9657	IDKmonitor® Adalimumab
K9646	IDKmonitor® Etanercept
K9658	IDKmonitor® Vedolizumab NEW
Cat. No.	Anti-Drug Ab (ADA) ELISAs
K9650	IDKmonitor® Infliximab Free ADA†
K9654	IDKmonitor® Infliximab Total ADA†
K9652	IDKmonitor® Adalimumab Free ADA
K9649	IDKmonitor® Golimumab Free ADA
K9651	IDKmonitor® Adalimumab Total ADA
K9653	IDKmonitor® Etanercept Free ADA
Cat. No.	Related assays
K9610	TNFα ELISA
K6927	IDK® Faecal Calprotectin ELISA

†Compatible with biosimilars: Inflectra™, Remsima™.

Biohit Healthcare Ltd

Pioneer House | Pioneer Business Park
North Road | Ellesmere Port
Cheshire CH65 1AD | UK
Tel. +44 (0)151 550 4 550
Fax. +44 (0)151 550 4 551
info@biohithealthcare.co.uk

www.biohithealthcare.co.uk

BIOHIT HealthCare
Innovating for Health

BIOHIT HealthCare

Innovating for Health

Therapeutic (Biologic) Drug Monitoring



TDMK96xx4EN2017/03

immun
diagnostik

Therapeutic Drug Monitoring

ELISAs

Background

Dysregulation of inflammatory cytokines and integrins has been indicated in several chronic inflammatory diseases including Rheumatoid and psoriatic Arthritis, and inflammatory bowel disease (IBD).

TNF α inhibitors and anti- α 4 β 7 blockers are biopharmaceutical drugs (antibodies) that target TNF α and α 4 β 7 to inhibit their actions. TNF α inhibitors are very effective at reducing the serum level of TNF α , controlling inflammation, minimising tissue damage, and improving symptoms. α 4 β 7-blockers prevent its interaction with mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) preventing gut-specific inflammatory processes.

Biological drugs provide an individualised therapeutic approach to managing inflammatory conditions and have shown to be effective in both monotherapeutic strategies and in combination with other anti-inflammatory drugs to improve quality of life, mucosal healing and reduce hospital admissions and surgery.

- 10-40% of patients fail to respond to therapy.
- 23-46% lose response after 12 months.
- Some patients experience unpredictable drug side effects (e.g. infusion reactions, serum sickness, opportunistic infections).
- Early treatment exposes about 30% of patients to side effects without benefit.

IDKmonitor® TDM ELISAs provide precise drug level measurements as well as Anti-Drug Antibody (ADA) detection from a blood sample.

Knowing the drug trough-level (TL) and ADA status prior to infusion/injection could help deliver significant cost savings where there is an increasing spend year on year by evaluating the potential benefit of biological therapies.

Clinical applications

- Predict and / or manage Loss of Response.
- Inform treatment decisions.
- Investigate Adherence.
- Assessment prior to stopping / re-starting therapy.

When TDM is used in combination with Clinical assessments an effective algorithm can be developed.

Drug Level Assays: Specificity is Key

IDKmonitor® Infliximab, Adalimumab, Etanercept and Vedolizumab drug level assays are coated with anti-drug antibodies to ensure that only the specific drug of interest is selected. This may be clinically relevant when monitoring patients that have undergone a switch from one biological drug to another.

ADA Assays: Total and Free

The presence of anti-drug antibodies is associated with low drug trough levels. Free ADA assays detect only Free ADAs that are not bound to drug. Total ADA assays are drug tolerant so that all ADAs can be detected even in the presence of drug. This can improve the sensitivity of testing since Free ADAs can be neutralized by the drug.

